Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) Latest Company News

Oct 27, 2026, 08:06 UTC
New Industries reported revenue of CNY 3.701 billion and net profit attributable to shareholders of CNY 1.391 billion for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 27, 2026, 08:06 UTC
New Industries reported third-quarter 2026 revenue of CNY 1.28 billion, up 3.03% year over year, and net profit attributable to shareholders of CNY 523 million, up 20.55%.
Source:
- finance.sina.cn
Sep 30, 2026, 10:35 UTC
Tianjin Hongshan Juye Equity Investment Partnership plans to reduce its stake in Shenzhen New Industries Biomedical Engineering by up to 1% (7.8572 million shares) via block trades within three months after 15 trading days from the announcement.
Source:
- finance.sina.cn
Sep 28, 2026, 08:05 UTC
Snibe obtained a Class III medical device registration certificate from the National Medical Products Administration for its herpes simplex virus type 2 nucleic acid detection kit (PCR-fluorescence probe method), valid until September 23, 2031.
Source:
- finance.sina.cn
Sep 16, 2026, 08:39 UTC
Shenzhen New Industries Biomedical Engineering received a medical device registration certificate from China's National Medical Products Administration for its fully automated nucleic acid detection and analysis system (model Molecision R8).
Source:
- finance.sina.cn
Aug 24, 2026, 07:56 UTC
Shenzhen New Industries Biomedical Engineering Co., Ltd. received a Class II Medical Device Registration Certificate from the Guangdong Provincial Drug Administration for its angiotensin-converting enzyme assay kit (FAPGG substrate method), valid from 2026-08-19 to 2031-08-18.
Source:
- finance.sina.cn

300832.SZ

New Industries reported revenue of CNY 3.701 billion and net profit attributable to shareholders of CNY 1.391 billion for the first three quarters of 2026.

New Industries reported third-quarter 2026 revenue of CNY 1.28 billion, up 3.03% year over year, and net profit attributable to shareholders of CNY 523 million, up 20.55%.

Tianjin Hongshan Juye Equity Investment Partnership plans to reduce its stake in Shenzhen New Industries Biomedical Engineering by up to 1% (7.8572 million shares) via block trades within three months after 15 trading days from the announcement.

Snibe obtained a Class III medical device registration certificate from the National Medical Products Administration for its herpes simplex virus type 2 nucleic acid detection kit (PCR-fluorescence probe method), valid until September 23, 2031.

Shenzhen New Industries Biomedical Engineering received a medical device registration certificate from China's National Medical Products Administration for its fully automated nucleic acid detection and analysis system (model Molecision R8).

Shenzhen New Industries Biomedical Engineering Co., Ltd. received a Class II Medical Device Registration Certificate from the Guangdong Provincial Drug Administration for its angiotensin-converting enzyme assay kit (FAPGG substrate method), valid from 2026-08-19 to 2031-08-18.